Valuation : Rein Therapeutics Inc.

Market Cap 65.74M 56.65M 53.12M 48.49M 91.34M 6.28B 91.63M 630M 246M 3.17B 247M 241M 10.52B P/E 2026 *
-1.66x
P/E 2027 * -1.64x
Enterprise Value 65.74M 56.65M 53.12M 48.49M 91.34M 6.28B 91.63M 630M 246M 3.17B 247M 241M 10.52B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.98%
Yield 2026 *
-
Yield 2027 * -
1 day+1.04%
1 week-4.08%
Current month+4.07%
1 month+4.07%
3 months-28.28%
6 months-33.27%
Current year-33.84%
1 week 0.76
Extreme 0.7621
0.82
1 month 0.69
Extreme 0.694
0.88
Current year 0.69
Extreme 0.694
2.1
1 year 0.69
Extreme 0.694
2.18
3 years 0.69
Extreme 0.694
7.42
5 years 0.69
Extreme 0.694
25.4
10 years 0.69
Extreme 0.694
309.6
Manager TitleAgeSince
Chief Executive Officer 60 2024-03-10
Director of Finance/CFO 64 2024-05-15
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 70 2013-05-31
Chairman 71 2023-10-30
Director/Board Member 60 2024-03-10
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Buy

Chairman

4,500 0.0058%
5/8/26 Free

Chief Executive Officer

-150,000 0.1922%
11/14/25
Voss Capital LP
BuyCompany 104,183 0.4424%
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%-4.08%-43.16%-53.77% 65.74M
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.12%+1.39%+44.64%+88.51% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+1.19%-2.88%-17.13%+450.07% 25.89B
+0.07%-9.81%+1.12%-15.86% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
-0.28%-0.55%+45.91%+142.30% 13.49B
Average -2.05%-4.02%+41.30%+159.91% 28.2B
Weighted average by Cap. -2.17%-3.50%+47.95%+144.89%

Financials

2026 *2027 *
Net sales - -
Net income -29.15M -25.12M -23.55M -21.5M -40.51M -2.79B -40.63M -279M -109M -1.41B -109M -107M -4.66B -37.01M -31.9M -29.91M -27.3M -51.43M -3.54B -51.59M -355M -138M -1.79B -139M -136M -5.92B
Net Debt - -
Logo Rein Therapeutics Inc.
Rein Therapeutics, Inc., formerly Aileron Therapeutics, Inc., is a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indications. The Company's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Employees
10
Date Price Change Volume
26-08-31 US$0.7674 +0.70% 38,351
26-08-28 US$0.7621 -2.64% 259,034
26-08-27 US$0.7828 -2.15% 136,466
26-08-26 US$0.8000 0.00% 324,711
26-08-25 US$0.8000 0.00% 276,754
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7621USD
Average target price
6.000USD
Spread / Average Target
+687.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNTX Stock